论文部分内容阅读
目的探讨尿激酶治疗急性心肌梗死的临床疗效。方法回顾性分析桂林市阳朔县人民医院2015年10月—2016年10月收治的急性心肌梗死患者40例,按照就诊先后顺序随机分为对照组与研究组,各20例。对照组予以常规治疗,研究组在对照组基础上加用尿激酶治疗,两组均持续治疗2周。比较两组患者临床疗效、12 h血管再通率、胸痛缓解时间、ST段下降≥50%时间、肌酸激酶同工酶(CK-MB)变化时间及并发症发生情况。结果研究组治疗总有效率为90.0%,高于对照组的55.0%(P<0.05)。研究组12 h血管再通率为85.0%,高于对照组的55.0%(P<0.05);研究组患者胸痛缓解时间、ST段下降≥50%时间、CK-MB变化时间短于对照组(P<0.05)。研究组并发症发生率为5.0%,低于对照组的30.0%(P<0.05)。结论尿激酶治疗急性心肌梗死的临床疗效确切,有利于控制患者CK-MB水平,且并发症少。
Objective To investigate the clinical efficacy of urokinase in the treatment of acute myocardial infarction. Methods Forty patients with acute myocardial infarction who were admitted to Yangshuo County People’s Hospital of Guilin City from October 2015 to October 2016 were retrospectively analyzed. They were randomly divided into control group and study group, with 20 cases in each group. The control group was given routine treatment. The study group was treated with urokinase on the basis of the control group, and both groups were treated for 2 weeks. The clinical curative effect, the rate of recanalization at 12 h, the relief time of chest pain, the time of ST segment declining more than 50%, the time of CK-MB and the complication were compared between the two groups. Results The total effective rate of the study group was 90.0%, which was higher than that of the control group (55.0%, P <0.05). In the study group, the rate of vascular recanalization at 12 h was 85.0%, which was significantly higher than that of the control group (55.0%, P <0.05). The relief time of chest pain, ST-segment decline ≥50%, CK- P <0.05). The complication rate was 5.0% in the study group, which was lower than 30.0% in the control group (P <0.05). Conclusion The clinical efficacy of urokinase in the treatment of acute myocardial infarction is definite, which is beneficial to control the level of CK-MB in patients with less complications.